This work explores the complex field of HER2 testing in the HER2-low breast cancer era,
with a focus on methodological aspects. We aim to propose clear positions to scientific …

Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of
pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The …

The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of
HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an …

In light of the significant clinical benefits of novel HER2-targeting antibody-drug conjugates
in advanced HER2-low expressing breast cancers in recent phases I and III clinical trials …

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide. 1 It is a
heterogeneous disease, comprising distinct biologic entities with different prognosis and …

The confirmation of the HER2-low paradigm is expected to have a major impact in breast
oncology. About half of all breast cancers harbor HER2-low expression, which can be …

Objectives We assessed the interobserver and interantibody reproducibility of HER2
immunohistochemical scoring in an enriched HER2-low–expressing breast cancer cohort …

HER2 status in breast cancer is assessed to select patients eligible for targeted therapy with
anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and …

Background In addition to providing a timely and accurate diagnosis, pathologists routinely
provide prognostic and predictive information to assist in the treatment of patients with …

Background HER2-low, defined by immunohistochemically (IHC) 1+ or 2+ with negative in
situ hybridization (ISH), has recently attracted attention as a novel classification in …